International Journal of Gynecological Cancer最新文献

{"title":"Surgical volume, structural quality, and compliance with European Society of Gynaecological Oncology quality indicators in endometrial and cervical cancer: a regional cross-sectional assessment.","authors":"Jvan Casarin, Tommaso Bianchi, Valter Torri, Mario G Melazzini, Alessandro Scardoni, Giuseppina M R Valenti, Carlo P Soatti, Monica Giordano, Fabio Landoni","doi":"10.1016/j.ijgc.2026.104847","DOIUrl":"10.1016/j.ijgc.2026.104847","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate regional compliance with European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial and cervical cancer and to assess the degree of centralization within a large regional Italian health care system.</p><p><strong>Methods: </strong>A cross-sectional population-based assessment was conducted across all 111 hospitals in Lombardy, Italy. Disease-specific questionnaires derived from European Society of Gynaecological Oncology quality indicators for endometrial and cervical cancer were distributed between January and March 2024. Surgical volumes for 2022-2023 were independently validated through administrative datasets using International Classification of Diseases diagnostic and procedural codes. Endometrial and cervical cancer were analyzed as separate disease-specific domains within a single regional quality-assessment framework.</p><p><strong>Results: </strong>A total of 2948 endometrial and 628 cervical cancer surgeries were performed during the study period. For endometrial cancer, 21 centers fulfilled all essential qualitative criteria, whereas 6 simultaneously met the volume, minimally invasive surgery, and nodal staging benchmarks. Nineteen centers performed more than one procedure per month and satisfied essential standards, accounting for 60% of regional cases; this monthly activity threshold was used only as an exploratory descriptor and not as an accreditation benchmark. Sentinel lymph node staging ≥70% and minimally invasive surgery ≥60% were achieved primarily in high-volume institutions. Molecular classification, including POLE testing, was available in 42.3% of centers in-house and through network collaboration in 42%. For cervical cancer, multi-disciplinary team availability exceeded 85%, but fertility-sparing protocols and structured ultra-staging were inconsistently implemented. Across both diseases, delays beyond 6 to 8 weeks for initiation of adjuvant therapy were frequent.</p><p><strong>Conclusions: </strong>Endometrial and cervical cancer care in Lombardy is partially aligned with European Society of Gynaecological Oncology-derived quality standards, with relevant disease-specific and institutional variability. These cross-sectional data provide a baseline for strengthening referral pathways, molecular diagnostic workflows, surgical staging quality, and time-to-treatment monitoring.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"36 9","pages":"104847"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the prophylactic use of compression garments reduce the risk of lower limb lymphedema after pelvic and/or inguinal lymphadenectomy for gynecological cancer? A systematic review.","authors":"Stefano Gentileschi, Giorgia Garganese, Simona Maria Fragomeni, Luca Tagliaferri, Anna Fagotti, Anna Amelia Caretto","doi":"10.1016/j.ijgc.2026.104840","DOIUrl":"10.1016/j.ijgc.2026.104840","url":null,"abstract":"<p><strong>Objective: </strong>Our goal was to assess whether prophylactic compression garments reduce lower-limb lymphedema after pelvic/inguinal lymphadenectomy for gynecologic malignancies.</p><p><strong>Methods: </strong>Preferred Reporting Items for Systematic Reviews and Meta-Analyses.-based systematic review. Eligible studies included primary interventional studies evaluating prophylactic lower-limb compression after pelvic and/or inguinal lymphadenectomy for gynecological malignancies; systematic/rapid reviews were considered for contextual background and reference checking; studies focused on treatment of established lymphedema or non-relevant populations/outcomes were excluded. The Population, Intervention, Comparison, Outcome question was: in women undergoing pelvic and/or inguinal lymphadenectomy for gynecological malignancy (P), does prophylactic use of compression garments (I), compared with no compression garments or non-compressive preventive strategies (C), reduce the incidence of lower-limb lymphedema (O)? PubMed, Scopus, Cochrane, LILACS, and SciELO were searched from inception through March8 2026, using Medical Subject Headings and free-text terms related to compression garments, lymphedema prevention, pelvic or inguinal lymphadenectomy, gynecological cancer, and lower-limb lymphedema.</p><p><strong>Results: </strong>A total of 536 full-text reports were assessed; 6 gynecological oncology randomized controlled trials met the Population, Intervention, Comparison, Outcome criteria; one additional mixed-population randomized controlled trial was treated as indirect evidence. Two systematic/rapid reviews were used for contextual background/reference checking; multimodal prevention studies were discussed as evidence for multimodal pathways because compression effects could not be isolated. Randomized controlled trials were heterogeneous: small trials using class I to II stockings did not demonstrate a significant reduction in lower-limb lymphedema, although they suggested a potential benefit. One randomized controlled trial (n = 64) showed a reduction in lymphedema incidence (3.4% vs 38.7%) with class II (23-32 mmHg) stockings worn for 12 months, alongside education and physical activity.</p><p><strong>Conclusions: </strong>Prophylactic compression-particularly early, prolonged class II stockings within structured rehabilitation-was associated with lower lymphedema incidence in some studies; evidence remains limited by small, heterogeneous trials, no meta-analysis, and multimodal interventions where compression effects cannot be isolated.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"36 9","pages":"104840"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility-sparing surgery in patients with advanced borderline ovarian tumors.","authors":"Tommaso Bianchi, Marta Jaconi, Elena De Ponti, Tommaso Grassi, Martina Bombelli, Giorgia Pecis Cavagna, Marta Seca, Jasmine Corti, Alessandra Inzoli, Daniela Giuliani, Gaetano Trezzi, Alessandra Casiraghi, Laura Russo, Stefania Chiari, Andrea Alberto Lissoni, Robert Fruscio","doi":"10.1016/j.ijgc.2026.104846","DOIUrl":"10.1016/j.ijgc.2026.104846","url":null,"abstract":"<p><strong>Objective: </strong>Data on fertility-sparing surgery in advanced borderline ovarian tumors are limited to retrospective series and suggest concerning fertility outcomes. We aimed to study the long-term fertility and reproductive outcomes of patients with stage IIA to IIIC borderline ovarian tumors treated with fertility-sparing surgery.</p><p><strong>Methods: </strong>This retrospective single-institution study included patients younger than 45 years with stage IIA to IIIC borderline ovarian tumors treated with fertility-sparing surgery from 1985 to 2021. Primary end points were the rates of pregnancies and live births among women attempting to conceive. Logistic regression models were used to evaluate the impact of different covariates on the occurrence of pregnancies.</p><p><strong>Results: </strong>A total of 86 patients were included in the study. The median follow-up was 182 months. Fifty patients (58%) actively attempted to conceive, 5 of whom were referred to a reproductive medicine center. Forty-two patients successfully achieved 76 pregnancies, and 63 live births occurred in 40 women, yielding an overall pregnancy and live birth rates of 84% and 80%, respectively. Of the 76 pregnancies, 40 occurred before any relapse, while 28 and 8 occurred after the first and second recurrences, respectively. Similarly, of the 63 live births, 35 occurred before any relapse, whereas 22 and 6 occurred after the first and second recurrences. Thirty-five (40.7%) patients underwent subsequent radical surgery, 29 for recurrence and 6 as completion surgery, after a median time of 96 months. The median age at radical surgery was 40 years. Among patients who did not undergo radical surgery, 11 experienced spontaneous menopause during follow-up at a median age of 41 years.</p><p><strong>Conclusions: </strong>Despite high recurrence rates, fertility-sparing surgery yields satisfactory fertility outcomes in patients with advanced borderline ovarian tumors, irrespective of disease stage or surgical approach, and should be considered both as a primary treatment strategy and as a feasible option for recurrent disease.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"36 9","pages":"104846"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the enthusiasm: a critical appraisal of topical human papillomavirus therapies.","authors":"Carlos Humberto Pérez","doi":"10.1016/j.ijgc.2026.104907","DOIUrl":"https://doi.org/10.1016/j.ijgc.2026.104907","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"36 9","pages":"104907"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer screening among transgender and gender diverse individuals: a systematic review and meta-analysis.","authors":"Amelia Srajer, John M Hutchinson, Amy Metcalfe, Darren R Brenner, Kristin A Black, Fiona Mattatall, Ioana Nicolau, Paul E Ronksley","doi":"10.1016/j.ijgc.2026.104850","DOIUrl":"10.1016/j.ijgc.2026.104850","url":null,"abstract":"<p><strong>Objective: </strong>To conduct a systematic review and meta-analysis of observational studies comparing cervical cancer screening participation and Pap cytology results between transgender/gender diverse individuals and cisgender female individuals.</p><p><strong>Methods: </strong>MEDLINE, EMBASE, and CINAHL were searched from database inception to January 7, 2026, by 2 independent reviewers. Primary observational studies reporting up-to-date cervical cancer screening and/or Pap test results in transgender/gender diverse individuals with a cervix compared with cisgender female individuals were included. Following the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines, data were independently extracted and critically appraised in duplicate.</p><p><strong>Results: </strong>Twenty-one studies were included, with sample sizes ranging from 116 to 238,036 participants or Pap tests. Twelve studies (57.1%) assessed up-to-date screening, and 9 (42.9%) reported un-satisfactory and abnormal Pap cytology. Compared with cisgender female individuals, transgender/gender diverse individuals had significantly lower odds of being up to date on cervical cancer screening (odds ratio 0.53, 95% confidence interval 0.35 to 0.79). Estimates were similar when stratified by self-report versus medical record data. Transgender/gender diverse individuals had more than 9-fold higher odds of un-satisfactory cytology (odds ratio 9.92, 95% confidence interval 7.42 to 13.26). Overall, abnormal cytology did not differ between groups (odds ratio 0.75, 95% confidence interval 0.37 to 1.49). In stratified analyses, lower odds of abnormal cytology for transgender/gender diverse individuals were observed among studies with mixed or unspecified testosterone use (odds ratio 0.44, 95% confidence interval 0.32 to 0.60) and in studies using all-comer versus atrophic cisgender comparators (odds ratio 0.44, 95% confidence interval 0.33 to 0.59). Findings for un-satisfactory cytology did not differ significantly across these strata. There was no evidence of small-study effects.</p><p><strong>Conclusions: </strong>Transgender/gender diverse individuals with a cervix are less likely to be up to date on cervical cancer screening and more likely to have un-satisfactory Pap cytology. Abnormal cytology appears similar overall but varies across testosterone use and comparator strata. These findings underscore the need for anatomically inclusive, evidence-based screening guidelines and evaluation of alternative approaches, such as primary human papillomavirus testing, to improve cervical cancer screening equity and effectiveness.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"36 9","pages":"104850"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148584303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study).","authors":"Rayan Kabirian, Mathilde de Saint Ghislain, Olivia Le Saux, Laurent Mathiot, Jean-Sébastien Frenel, Paule Augereau, Alexandra Forestier, Jean David Fumet, Lauriane Eberst, Stanislas Quesada, Elsa Kalbacher, Céline Lescure, Thibault De La Motte Rouge, Juan Francisco Grau Bejar, Solenn Barraud, Thomas Genevee, Diana Bello Roufai, Manuel Rodrigues, Alexandra Leary","doi":"10.1016/j.ijgc.2026.104867","DOIUrl":"10.1016/j.ijgc.2026.104867","url":null,"abstract":"<p><strong>Objective: </strong>Immune checkpoint inhibitors have significantly improved the outcome of patients with cervical and endometrial cancers but the benefit of immune checkpoint inhibitor rechallenge is unknown. We aimed to evaluate the efficacy and safety of immune checkpoint inhibitor rechallenge in this population.</p><p><strong>Methods: </strong>This national retrospective study was conducted in 10 French academic centers between November 2015 and June 2025, to identify patients with metastatic cervical or endometrial cancer who were rechallenged with an immune checkpoint inhibitor. Rechallenge regimens included anti-programmed cell death protein 1/anti-programmed death-ligand 1 agents, administered alone or in combination with chemotherapy or targeted therapy. The primary endpoint was overall objective response rate during initial immune checkpoint inhibitor therapy and subsequent rechallenge. Secondary endpoints included progression-free survival following the initial and subsequent immune checkpoint inhibitor exposures, and safety (immune-related adverse events).</p><p><strong>Results: </strong>Thirty-nine patients with cervical (n = 20) or endometrial (n = 19) cancer who received immune checkpoint inhibitor rechallenge after prior immune checkpoint inhibitor exposure were identified. Ten patients who were rechallenged after prior immune checkpoint inhibitor exposure discontinuation for toxicity without subsequent disease progression were excluded from the efficacy analysis and retained for safety analysis only, yielding an efficacy cohort of 29 patients. Objective response rate was 76% (22/29) with prior immune checkpoint inhibitor exposure and 52% (15/29) upon rechallenge. Most patients received anti-programmed cell death protein 1-based therapy at rechallenge (92%), and 72% were treated without concurrent chemotherapy. Median progression-free survival decreased from 11.0 months (95% confidence interval 8.7 to 19.0) with prior immune checkpoint inhibitor exposure to 6.0 months (95% confidence interval 4.0 to 16.0) with immune checkpoint inhibitor rechallenge. Regarding safety, immune-related adverse events leading to prior immune checkpoint inhibitor exposure discontinuation were mainly colitis (32%) and hepatotoxicity (11%). During rechallenge, 13% of patients discontinued immune checkpoint inhibitor rechallenge due to toxicity.</p><p><strong>Conclusions: </strong>Immune checkpoint inhibitor rechallenge in cervical and endometrial cancer is feasible, demonstrates meaningful anti-tumor activity, and is associated with a manageable safety profile.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"104867"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of cervical involvement in advanced endometrial cancer.","authors":"Vanesa Delso, Rafael Sánchez-Del Hoyo, María D Fasero, Pluvio J Coronado","doi":"10.1016/j.ijgc.2026.104489","DOIUrl":"10.1016/j.ijgc.2026.104489","url":null,"abstract":"<p><strong>Objective: </strong>Endometrial cancer is the most common gynecologic malignancy in the United States and a leading cause of gynecologic cancer mortality worldwide. Although most cases are diagnosed early, 15% to 25% present with advanced disease and have poor outcomes. The prognostic significance of cervical involvement in advanced endometrial cancer remains unclear. This study evaluated cervical stromal involvement using the International Federation of Gynecology and Obstetrics 2023 classification in a large advanced-stage cohort.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of 363 patients with advanced-stage endometrial cancer surgically treated at a single institution between 2005 and 2022. Cervical involvement was defined as stromal infiltration. Clinical, pathological, and treatment variables were collected. Disease-free survival and overall survival were assessed with Kaplan-Meier estimates and Cox proportional hazards models. Disease-free survival was further analyzed adjusting for American Society of Anesthesiologists (ASA) classification, tumor grade, and lymphovascular space invasion.</p><p><strong>Results: </strong>Cervical involvement was observed in 122 patients (33.6%). Univariate analysis showed reduced disease-free survival in patients with cervical involvement (5-year disease-free survival: 39.8% vs 48.3%; hazard ratio [HR] 1.4, 95% confidence interval [CI] 1.04 to 1.87, p = .02), while overall survival differences were not significant. After adjustment, cervical involvement lost independent prognostic significance (disease-free survival: HR 1.20, 95% CI 0.85 to 1.69, p = .29). ASA status, high tumor grade, and lymphovascular space invasion remained strong predictors of recurrence. Surgical approach did not impact survival outcomes.</p><p><strong>Conclusions: </strong>Cervical involvement reflects tumor aggressiveness but is not an independent predictor of recurrence or survival in advanced endometrial cancer.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"104489"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146179395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic impact of celiac lymph node involvement in advanced ovarian cancer.","authors":"Pauline Prost, Martina Aida Angeles, Bertille Segier, Elodie Gauroy, Giulio Ricotta, Mathilde Del, Gwenael Ferron, Guillaume Bataillon, Laurence Gladieff, Bastien Cabarrou, Sarah Betrian, Alejandra Martinez","doi":"10.1016/j.ijgc.2026.104653","DOIUrl":"10.1016/j.ijgc.2026.104653","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the prognostic impact of celiac lymph node involvement in patients with advanced high-grade serous ovarian cancer.</p><p><strong>Methods: </strong>We conducted a retrospective, single-center study including patients who underwent celiac lymph node resection during either upfront or interval complete cytoreductive surgery as frontline treatment for advanced high-grade serous ovarian cancer between January 2002 and December 2022. Patients were categorized into 2 groups based on celiac lymph node status. Univariable and multi-variable analyses were performed, and survival rates were estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>Among 820 patients who underwent cytoreductive surgery for ovarian cancer during the study period, 65 (7.9%) had celiac lymph node resection and were included. Celiac lymph node metastases were identified in 42 (64.6%) cases. Celiac lymph node-positive patients had a higher tumor burden (p =.001), more frequent bowel involvement (p =.026), and higher rates of left hemicolectomy (17.1% vs 0.0%) and inguinal lymphadenectomy (16.7% vs 0.0%). Median overall survival was 30.9 months in the celiac lymph node-positive group and 50.6 months in the celiac lymph node-negative group (p =.270); median disease-free survival was 10.8 and 14.6 months (p =.082), respectively. In multi-variable analysis, celiac lymph node involvement was significantly associated with decreased disease-free survival (hazard ratio 2.87 [1.38 to 5.93], p =.005).</p><p><strong>Conclusions: </strong>Celiac lymph node involvement is associated with a higher tumor burden and significantly associated with a decrease in disease-free survival in cases of advanced high-grade serous ovarian cancer. These results highlight the need to identify celiac lymph node involvement for better risk stratification.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"104653"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How long is enough? Immunotherapy duration in mismatch repair deficient endometrial cancer.","authors":"Juliana Mandarano de Mattos, Amanda de Araújo Dias, Júlia Chain Martins, Aniceto Lopes da Silva Neto, Mariana Scaranti","doi":"10.1016/j.ijgc.2026.104797","DOIUrl":"10.1016/j.ijgc.2026.104797","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"36 9","pages":"104797"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on \"Role of the novel optoelectronic imaging tracing system in cervical cancer screening: preliminary outcomes of a multi-center study\" by Xiao Shang et al.","authors":"Qian Wu, Xinyi Qiu, Ruisi Peng","doi":"10.1016/j.ijgc.2025.102873","DOIUrl":"10.1016/j.ijgc.2025.102873","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102873"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}